Trial Profile

A compassionate use trial to investigate the safety and efficacy of dendritic cell vaccines in patients with various types of tumours

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 May 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dendritic cell vaccines-Medigene Immnotherapies (Primary)
Indications Acute myeloid leukaemia; Glioblastoma; Lung cancer; Prostate cancer
Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

09 May 2018 According to MediGene media release, data from this trial were presented at the AACR annual conference.
04 Apr 2017 Results published in the MediGene AG Media Release
04 Apr 2017 Results (n = 5) were presented at the American Association for Cancer Research (AACR) Annual Meeting, according to a MediGene AG media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com